Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Pazopanib hydrochloride 433.4mg equivalent to Pazopanib 400 mg
Teva Pharma (New Zealand) Limited
400 mg
Film coated tablet
Active: Pazopanib hydrochloride 433.4mg equivalent to Pazopanib 400 mg Excipient: Hypromellose Macrogol 400 Magnesium stearate Microcrystalline cellulose Polysorbate 80 Povidone Purified water Sodium starch glycolate Titanium dioxide
Prescription
Renal cell carcinoma (RCC) Pazopanib (Teva) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (RCC).
Package - Contents - Shelf Life: Blister pack, PVC/PVdC/PE-Al - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVdC/PE-Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with PP CRC - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with PP CRC - 60 tablets - 36 months from date of manufacture stored at or below 25°C
2022-04-11